Entos Pharmaceuticals News, Researches and Articles

About us

We do not want children to die from a disease that can be cured. We want to give hope to families and ensure that all children with DMD are treated and regain their health.

Latest Articles

ITF Therapeutics Announces Publication of Positive Long-Term Data Reinforcing Duvyzat (Givinostat) Efficacy and Safety as a Treatment for Duchenne Muscular Dystrophy

Press Releases August 25, 2025 0

ITF Therapeutics affiliate of Italfarmaco, today announced publication of...

Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy

Press Releases August 20, 2025 0

Keros Therapeutics today announced the U.S. Food and Drug...

ITF Therapeutics Launching A Study to Evaluate the Real-World Experience of Duvyzat (Givinostat) in Patients With Duchenne Muscular Dystrophy

Research August 19, 2025 0

The purpose of this prospective observational study (NCT07127978) is...

Frequently Asked Questions About Elevidys Used for Duchenne Muscular Dystrophy

Approved Treatments December 26, 2024 5

A genetic condition known as Duchenne muscular dystrophy (DMD)...

Potential Upcoming New Gene Therapies for Duchenne Muscular Dystrophy

Research January 5, 2025 7

The results of new gene therapy studies for Duchenne...

Duchenne Muscular Dystrophy: Treatment & Cost

Editorials January 2, 2025 1

The excitement you feel until your child is born...

Entos Pharmaceuticals

Must Read

Entrada Therapeutics Begins Clinical Trials in Europe for Exon 44 and Exon 45 Skipping Therapies

Wellcome Trust Donates £10 Million to Treat Rare Diseases

Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies